A alarming phenomenon is surfacing within the drug scene: "Pink copyright," formally known as Flunitramadol. This manufactured opioid is being marketed as a crystal , often presented as copyright, posing a serious risk to people. Its seemingly low cost and easy accessibility are leading its swift